Paul Rutgeerts Selected Research

infliximab (Remicade)

06/2008	Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
09/2007	Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
06/2007	Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
04/2007	The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
04/2007	Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors.
02/2007	Predictors of early response to infliximab in patients with ulcerative colitis.
05/2006	Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study.
03/2006	Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
01/2006	No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease.
12/2005	Infliximab for induction and maintenance therapy for ulcerative colitis.
11/2005	Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.
07/2004	Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
02/2004	Infliximab maintenance therapy for fistulizing Crohn's disease.
02/2004	Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
02/2003	Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
02/2003	Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease.
09/2002	Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
07/2002	NOD2/CARD15 does not influence response to infliximab in Crohn's disease.
05/2002	Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Articles by Research Topic

Disease

37	Crohn Disease (Crohn's Disease) 06/2008 - 01/2002
12	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 06/2008 - 07/2004
10	Ulcerative Colitis 04/2007 - 02/2003
2	Colitis 01/2007 - 08/2006
1	Sclerosing Cholangitis 06/2007
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 12/2005
1	Progressive Multifocal Leukoencephalopathy 07/2005
1	Diarrhea 06/2005
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 08/2003
1	Collagenous Colitis 01/2002

Drug/Important Bio-Agent (IBA)

19	infliximab (Remicade)FDA Link 06/2008 - 05/2002
6	AntibodiesIBA 06/2008 - 03/2005
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2006 - 08/2002
3	CDP870 FDA Link 03/2008 - 09/2005
3	adalimumab (Humira)FDA Link 06/2007 - 02/2006
3	Cyclosporine (Ciclosporin)FDA LinkGeneric 06/2006 - 10/2003
3	C-Reactive ProteinIBA 01/2006 - 09/2004
3	natalizumab (Tysabri)FDA Link 11/2005 - 01/2003
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2006 - 08/2003
1	Nonesterified Fatty Acids (NEFA)IBA 04/2008
1	Phosphopyruvate Hydratase (Enolase)IBA 03/2008
1	InterferonsIBA 12/2007
1	AntigensIBA 11/2007
1	Chemokine CCL5IBA 06/2007
1	4AZA1378IBA 01/2007
1	4AZA2096IBA 08/2006
1	recombinant human tumor necrosis factor-binding protein-1IBA 07/2006
1	Lymphotoxin-alpha (Lymphotoxin)IBA 05/2006
1	SteroidsIBA 05/2006
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 06/2005
1	P-GlycoproteinIBA 06/2005
1	Tacrolimus (Prograf)FDA Link 06/2005
1	OrnidazoleIBA 04/2005
1	AutoantibodiesIBA 11/2004
1	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 10/2004
1	Technetium Tc 99m Exametazime (Ceretec)FDA Link 10/2004
1	6-Mercaptopurine (Mercaptopurine)FDA LinkGeneric 09/2004
1	Mesalamine (Mesalazine)FDA LinkGeneric 09/2004
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 08/2004
1	ChemokinesIBA 07/2004
1	daclizumab (dacliximab)FDA Link 02/2003
1	Interleukin-12 (IL 12)IBA 10/2002
1	Interferon-gamma (Interferon, gamma)IBA 10/2002
1	Sodium Glutamate (Accent)IBA 05/2002
1	Interleukin-10 (Interleukin 10)IBA 01/2002
1	Budesonide (Pulmicort)FDA LinkGeneric 01/2002

Therapy/Procedure

2	Colectomy 06/2006 - 10/2004
1	Biological Therapy 07/2006
1	Transplants (Transplant) 06/2005
1	Drug Therapy (Chemotherapy) 02/2005